BXP154 is a novel hemostatic agent developed by Bio 54, LLC, currently in Phase 2 clinical trials for treating post-punch biopsy bleeding in anticoagulated patients. The drug aims to provide rapid and effective hemostasis, addressing a significant unmet need in this patient population.